Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End

 
• By Mandy Jackson

Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.

GoldKeyInPuzzle_1200x675
Selling Otezla to appease the FTC is key to closing the Bristol-Celgene merger on time. • Source: Shutterstock

More from Deals

More from Business